(RDY) Dr. Reddy’s Laboratories - Ratings and Ratios

Dr. Reddys Laboratories Ltd ADR (NYSE:RDY) is a global integrated pharmaceutical company specializing in the development, manufacture, and marketing of a wide range of pharmaceutical products. The company operates through three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment focuses on producing prescription and over-the-counter drugs, including generic versions of branded medications and biologics. The PSAI segment specializes in active pharmaceutical ingredients (APIs) and intermediates, offering contract research services and custom synthesis for clients. The Others segment encompasses the companys research and development efforts in specialized therapeutic areas such as oncology and inflammation, as well as its digital healthcare initiatives and IT-enabled business support services. Dr. Reddys products cater to multiple therapeutic categories, including gastrointestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Headquartered in Hyderabad, India, the company was founded in 1984 and has established itself as a key player in the global generics market, with a strong emphasis on innovation and affordability.

Dr. Reddys Laboratories is listed on the NYSE under the ticker symbol RDY and is classified under the Pharmaceuticals sub-industry. With a market capitalization of approximately $11.01 billion USD, the company demonstrates a price-to-earnings (P/E) ratio of 17.63 and a forward P/E of 15.29, indicating moderate valuation expectations. The price-to-book (P/B) ratio of 2.99 suggests that the stock is trading at a premium relative to its book value. The companys return on equity (RoE) stands at 16.89%, reflecting efficient profitability. From a technical standpoint, the stocks average volume over the past 20 days is 2,863,128 shares, with a last price of $13.68. The stock is currently trading below its 200-day simple moving average (SMA) of $14.80, while its 20-day and 50-day SMAs are $13.19 and $13.20, respectively. The average true range (ATR) of 0.30 indicates relatively low volatility in recent trading sessions.